O/W lipid emulsions for parenteral drug delivery. IV. Changes in the pharmacokinetics and pharmacodynamics of a highly lipophilic drug, menatetrenone

Journal of Drug Targeting

Volumn 6, Issue 3, 1998, Pages 183-189

  Sakaeda, Toshiyuki ^a   Kakushi, Hisato ^a   Shike, Tsutomu ^a   Takano, Kyoji ^a   Harauchi, Toshio ^a   Hirata, Masaharu ^a   Hirano, Koichiro ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

Drug delivery system; Menatetrenone; O W lipid emulsion; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BLOOD CLOTTING FACTOR 7; DECARBOXYPROTHROMBIN; LIPID EMULSION; MENATETRENONE; OIL; PROTHROMBIN; VITAMIN K GROUP; WARFARIN; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG TISSUE LEVEL; INTRAVENOUS DRUG ADMINISTRATION; LIVER; LUNG; MALE; MICELLE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; SPLEEN;

EID: 0032421954     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/10611869808997892     Document Type: Article

References (26)

1. Alving, C.R. (1983). Delivery of liposome-encapsulated drugs to macrophages. Pharm. Ther., 22, 407-424.
2. Collins-Gold, L.C., Lyons, R.T. and Bartholow, L.C. (1990). Parenteral emulsions for drug delivery. Adv. Drug Delivery Rev., 5, 189-208.
3. Davis, S.S., Hadgraft, J. and Palm, K.J. (1985). Medical and pharmaceutical applications of emulsions. In P. Becher, (ed.), Encyclopedia of Emulsion Technology (Marcel Dekker, New York), pp. 159-238.
4. Davis, S.S., Washington, C., West, P., Illum, L., Liversidge, G., Sternson, L. and Kirsh, R. (1987). Lipid emulsions as drug delivery systems. Ann. N. Y. Acad. Sci., 507, 75-88.
5. Fidler, I.J. (1986). Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Immunol. Immunother., 21, 169-173.
6. Hansch, C., Leo, A., Unger, S.H., Kim, K.H., Nikaitani, D. and Lien, E.J. (1973). Aromatic substituent constants for structure-activity correlations. J. Med. Chem., 16, 1207-1216.
7. Harauchi, T., Takano, K., Matsuura, M. and Yoshizaki, T. (1986). Liver and plasma levels of descarboxyprothrombin (PIVKA II) in vitamin K deficiency in rats. Jpn. J. Pharmacol., 40, 491-499.
8. 1 and the application of them to lipid microsphere (LM) preparations. Jpn. J. Inflamm., 8, 243-246.
9. Jeppsson, R.I. (1976). Plasma levels of diazepam in the dog and the rabbit after two different injection formulations, emulsion and solution. J. Clin. Pharm., 1, 181-187.
10. Kakutani, T., Nishihara, Y., Takahashi, K. and Hirano, K. (1991). O/W lipid microemulsion for patenteral drug delivery. Proc. Int. Symp. Control Rel. Bioact. Mater., 18, 359-360.
11. Leo, A., Jow, P.Y.C., Silipo, C. and Hansch, C. (1975). Calculation of hydrophobic constant (log P) from π and f constants. J. Med. Chem., 18, 865-868.
12. Matsuura, M., Satoh, S., Kobayashi, F., Uchida, K. and Matsubara, T. (1989). Vitamin K-reversible hypoprothrombinemia in rats: Comparison of hypoprothrombinemic changes in various strains of rats caused by vitamin K deficiency and antibiotic treatment. J. Toxicol. Sci., 14, 165-180.
13. Mizushima, Y. (1991). Lipo-prostaglandin preparations. Prostagl. Leukotr. Essent. Fatty Acids, 42, 1-6.
14. Mizushima, Y., Igarashi, R., Hoshi, K., Sim, A.K., Cleland, M.E., Hayashi, H. and Goto, J. (1987). Marked enhancement in antithrombotic activity of isocarbacyclin following its incorporation into lipid microspheres. Prostaglandins, 33, 161-168.
15. Moghimi, S.M. and Davis, S.S. (1994). Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection. CRC Crit. Rev. Ther. Drug Carrier Systems, 11, 31-59.
16. New, R.R.C., Chance, M.L., Thomas, S.C. and Peters, W. (1978). Antileishmanial activity of antimonials entrapped in liposomes. Nature, 272, 55-56.
17. Prankerd, R.J. and Stella, V.J. (1990). The use of oil-in-water emulsions as a vehicle for parenteral drug administration. J. Parent. Sci. Technol., 44, 139-149.
18. Sakaeda (nee Kakutani), T., Takahashi, K., Nishihara, Y. and Hirano, K. (1994). O/W lipid emulsions for parenteral drug delivery. I. Pharmacokinetics of the oil particles and incorporated Sudan II. Biol. Pharm. Bull., 17, 1490-1495.
19. Sakaeda (nee Kakutani), T. and Hirano, K. (1995). O/W lipid emulsions for parenteral drug delivery. II. Effect of composition on pharmacokinetics of incorporated drug. J. Drug Targeting, 3, 221-230.
20. Sakaeda (nee Kakutani), T. and Hirano, K. (1998). O/W lipid emulsions for parenteral drug delivery. III. Lipophilicity necessary for incorporation in oil particles even after intravenous injection. J. Drug Targeting, in press.
21. Scherphof, G.L. and van Borssum Waalkes, M. (1994). Release of active drug from intercellular liposomal prodrug depots in macrophages controlled by liposome composition. J. Liposome Res., 4, 427-437.
22. Shah, D.V., Swanson, J.C. and Suttie, J.W. (1984). Abnormal prothrombin in the vitamin K-deficient rat. Thrombos. Res., 35, 451-458.
23. Singh, M. and Ravin, L.J. (1986). Parenteral emulsions as drug carrier systems. J. Parent. Sci. Technol., 40, 34-41.
24. Storm, G., Regts, J., Bijnen, J.H. and Roerdink, F.H. (1989). Processing of doxorubicin-containing liposomes by liver macrophages in vitro. J. Liposome Res., 1, 195-210.
25. Tardi, P.G., Boman, N.L. and Cullis, P.P. (1996). Liposomal doxorubicin. J. Drug Targeting, 4, 129-140.
26. Vermeer, C. and Hamulyak, K. (1991). Pathophysiology of vitamin K-deficiency and oral anticoagulants. Thromb. Haemostas., 66, 153-159.